September 22, 2025
In a landmark achievement, Tempus AI, Inc. (NASDAQ: TEM) has secured a 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its novel RNA-based Tempus xR IVD device. This development holds significant implications not only for the company but also for the broader landscape of precision medicine and drug development. As a frontrunner in adopting artificial intelligence to enhance precision medicine and patient care, Tempus is well-positioned to harness this regulatory milestone to drive growth and innovation.The Tempus xR IVD device is an in vitro diagnostic tool designed for RNA sequencing, offering a sophisticated glimpse into the biology underlying various diseases. By capturing a vast arr...
May 5, 2025
Leveraging AI in Psychiatry: Tempus Notetaker Revolutionizes Clinical DocumentationIn a significant leap for mental health care, Tempus AI, Inc. has unveiled its latest innovation, Notetaker, an artificial intelligence-driven clinical assistant designed to foster efficiency and enhance precision in psychiatric practice. As mental health professionals grapple with the challenges of providing quality care amid administrative burdens, this tool emerges as a crucial solution to streamline documentation and improve patient outcomes. The Burden of Documentation in PsychiatryFor psychiatrists, the intricacies of diagnosis and therapy extend far beyond patient interactions. The demands of meticulous record-keeping...
February 21, 2025
In an era where artificial intelligence (AI) and precision medicine are becoming integral to cancer treatment, a significant collaboration has emerged between Tempus AI, Inc. and Stemline Therapeutics, a subsidiary of the Menarini Group. Announced on February 21, 2025, this partnership aims to leverage Tempus s Next AI-enabled care pathway intelligence platform to enhance care for patients with metastatic breast cancer, particularly in determining the appropriateness of ESR1 testing. The FactsTempus AI, a prominent player in the adoption of AI technology within healthcare, specializes in harnessing data to inform personalized treatment protocols for cancer patients. The company s latest venture involves the ...
September 13, 2024
Chicago - Tempus AI, Inc. (NASDAQ: TEM), a technology company at the forefront of artificial intelligence and precision medicine, continues to set new benchmarks in the healthcare sector. In a significant stride forward, the company recently announced that four of its abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024. This influential event will be held in Barcelona, Spain, from September 13-17, 2024.The ESMO Congress, known for its role as a global hub for oncology professionals, will provide Tempus with an invaluable platform to share the latest research and developments. Eric Lefkofsky, Founder and CEO of Tempus, expressed enthusiasm over this...
July 10, 2024
Tempus Surpasses 500 Research Publications: A Major Milestone for Artificial Intelligence in Precision MedicineTempus AI, Inc., a renowned player in the field of artificial intelligence (AI) and precision medicine, recently achieved an impressive milestone with over 500 research publications. Over the past eight years, Tempus has demonstrated its commitment to rigorous scientific research to validate its diagnostic offerings. It has also collaborated with biopharma and academic partners to publish research supported by its extensive multimodal data library. This landmark achievement reflects Tempus relentless pursuit of advancing healthcare through AI technology and its relentless dedication to producing hi...
Sources:
Tempus Ai Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tempus Ai Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
